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Introduction
Duchenne muscular dystrophy (DMD) is the most common he-
reditary degenerative muscular disorder, with an incidence of ap-
proximately 1 in 3500 male births.
1) Becker muscular dystrophy (BMD) 
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is less common, affecting approximately 1 in 30000 males. It cau-
ses relatively milder muscle weakness and has a better prognosis 
than DMD.
2) Both diseases result from mutations of the dystrophin 
gene, which is on chromosome Xp21.1 and encodes for the mem-
brane protein dystrophin. The dystrophin links the muscle cytoskele-
ton to the extracellular matrix by interacting with a large number 
of membrane proteins,
3) protecting both cardiac and skeletal myo-
cytes against contraction-induced damage.
4) Defects or inactiva-
tion of the dystrophin protein lead to cardiomyocyte death and myo-
cardial fibrosis, eventually resulting in dilated cardiomyopathy (DCM).
3-5)
Early diagnosis and treatment of DCM may lead to ventricular re-
verse remodeling in DMD and BMD patients.
6) Angiotension-con-
verting enzyme (ACE) inhibitors have been evaluated in previous 
studies for their ability to prevent cardiomyopathy in patients with 
DMD.
7-9) However, there is controversy regarding the efficacy of β- 
blockers in the treatment of left ventricular (LV) dysfunction in pa-
tients with DMD.
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The purpose of this study was to evaluate the efficacy of enala-
pril (an ACE inhibitor) and carvedilol (a β-blocker) on LV dysfunction 
in adolescent patients with DMD or BMD by multiple echocardio-
graphic variables in a single center.
Subjects and Methods
Study protocol and subjects
This study comprises a prospective, randomized but unblinded me-
dication trial. We reviewed the patients’ clinical data from medical 
records, including sex, body weight, height, age at the time of diag-
nosis with muscular dystrophy, age at the onset of LV dysfunction, 
and previously and currently prescribed medication.
We newly prescribed enalapril or carvedilol to 23 patients (12.6±3.7 
years; median 13 years) randomly from July 2008 to August 2010 
(enalapril group, 13 patients; carvedilol group, 10 patients). Enala-
pril was initially prescribed at a dose of 0.05 mg/kg per day and slow-
ly increased over a period of 1-3 months to a daily dose of 0.1 mg/kg. 
Carvedilol was initially prescribed at a dose of 0.075 mg/kg every 
12 hours and increased every 1-3 months to a target dose of 1 mg/
kg per day. Informed consent was obtained from all participants or 
their parents and the study protocol was approved by the Institu-
tional Ethics Committee of our institution.
Echocardiography 
Echocardiography was performed using a Vivid 7 scanner (GE Vi-
ngmed Ultrasound, Horten, Norway) and an appropriately sized trans-
ducer probe (3 MHz or 5 MHz). The measurements were taken by a 
single experienced observer and the average of 3 measurements of 
all LV parameters was used for analysis. Patients were examined by 
transthoracic 2-dimensional, 3-dimensional, M-mode, pulse-wave 
Doppler, and tissue Doppler echocardiography. Before and after the 
administration of enalapril or carvedilol, LV functional parameters 
of systolic function {fractional shortening (FS), ejection fraction (EF), 
LV peak global longitudinal strain, and systolic myocardial velocities 
at the basal segments of the LV free wall and septal wall}, diastolic 
function (E velocity, A velocity, the E/A ratio of mitral inflow, and dia-
stolic myocardial velocities and their ratio to the basal segments of 
Table 1. Left ventricular functional parameters in echocardiographic exami-
nations
LV systolic function
    Fractional shortening (FS)=(LVIDd-LVIDs)/LVIDd
    Ejection fraction (EF)=(LVIDd
3-LVIDs
3)/LVIDd
3
    LV peak global longitudinal strain 
    Myocardial velocities: Sm in LV lateral and septal wall
LV diastolic function*
    E velocity: peak early diastolic transmitral flow velocity
    A velocity: peak diastolic transmitral flow velocity 
      during atrial contraction 
    E/A ratio=E velocity/A velocity
Myocardial velocities: Em, Am, Em/Am in LV lateral and septal wall
LV global function
    Index of myocardial performance (Tei index)=(IVRT+IVCT)/ET
LV mass index (g/m
2)=[(1.04){(LVEDd+LVSWd+LVPWd)
3
  -LVEDd
3}-13.6]/BSA
*Pulse-wave Doppler echocardiography at the tip of the mitral valve using 
a sample volume from the apical 4-chamber view. LV: left ventricular, 
LVIDd: LV end-diastolic internal diameter, LVID: LV end-systolic internal di-
ameter, LVEDd: LV end-diastolic diameter, IVRT: isovolumic relaxation time, 
IVCT: isovolumic contraction time, ET: ejection time, Sm: systolic myocardial 
velocity, Em: early diastolic myocardial velocity, Am: late diastolic myocar-
dial velocity, LVSWd: LV end-diastolic septal wall thickness, LVPWd: LV end-
diastolic posterior wall thickness, BSA: body surface area 
A   B  
Fig. 1. Left ventricular (LV) peak longitudinal strain and 3-dimensional LV volume measurement. A: LV peak global longitudinal strain at the apical 4-cham-
ber view, which was -17% in 1 patient. B: 3-Dimensional LV volume measurement and acquisition of ejection fraction by tri-plane volumetry, which was 
36.8% in 1 patient.186  Enalapril and Carvedilol Against Cardiomyopathy in Muscular Dystrophy
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the LV free wall and septal wall), the LV index of myocardial perform-
ance (Tei index), and the LV mass index were evaluated. Results were 
obtained using indices listed in Table 1 by appropriate measure-
ment.
11-16)
To identify LV dilatation, we measured LV end-diastolic diameter 
(LVEDd) and LV end-systolic diameter (LVESd) in the M-mode and 
divided the ventricular dimensions by body surface area (BSA). We 
also measured LV peak global longitudinal strain by 2-dimensional 
echocardiography from the apical 4-chamber view to additionally 
estimate LV systolic function (Fig. 1A). To evaluate the change of LV 
volume before and after treatment, we measured LV end-diastolic 
volume (LVEDv) and LV end-systolic volume (LVESv) using the tri-
plane volumetry method, which was indexed by BSA (Fig. 1B). 
Left ventricular ejection fraction smaller than 55% and/or LV FS 
smaller than 28% were considered as LV systolic dysfunction. The 
age at first abnormal echocardiographic results was considered as 
the age of LV dysfunction onset. 
Measurement of plasma levels of brain natriuretic peptide
On the day of echocardiographic examination, venous blood was 
withdrawn from each patient for measurement of plasma brain na-
triuretic peptide (BNP) levels using a specific chemiluminescence 
immunoassay. BNP levels were also checked at the time of follow-up 
echocardiography in each group. The upper normal limit was 100 
pg/mL.
Statistical analysis
Data were analyzed using the Statistical Package for the Social 
Sciences (SPSS) software (version 17.0; SPSS Inc., Chicago, IL, USA). 
All data are expressed as mean±standard deviation. The Mann-
Whitney test was applied for comparing enalapril-treated patients 
and carvedilol-treated patients. Wilcoxon-signed rank test was used 
to compare the echocardiogram results before and after the treat-
ment with enalapril or carvedilol. A p<0.05 was considered statis-
tically significant. 
Results
Patient characteristics
Twenty-three male patients who presented with LV systolic dys-
function (22 with DMD and 1 with BMD) were enrolled. Mean age at 
diagnosis of muscular dystrophy was 7.7±5.0 years (median, 7 years), 
and the mean age at onset of LV dysfunction was 12.6±3.7 years 
(median, 13 years). The average follow-up duration was 20.1±8.9 
months. Among the 23 patients, enalapril was prescribed to 13 pa-
tients (mean age at start of treatment, 12.2±3.6 years; median age, 
12 years), and carvedilol was prescribed to 10 patients (mean age at 
start of treatment, 13.6±3.9 years; median age, 13 years). Patients 
in the enalapril and carvedilol groups were followed up for an aver-
age 20.8±10.5 years and 19.3±7.0 months, respectively. There were 
no significant differences in the mean age at diagnosis of muscu-
lar dystrophy, the average age at onset of LV dysfunction, or aver-
age follow-up duration between the enalapril and carvedilol group.
Among the 23 patients, 18 (78.3%) patients were wheelchair-
bound by approximately 10 years of age and the prevalence of 
wheelchair confinement was similar in both groups (76.9% in the 
enalapril group and 80% in the carvedilol group; p=0.762). 
Changes in left ventricular echocardiographic parameters 
(Table 2, 3, 4)
Left ventricular dimension and volume change
In the enalapril group, LVEDd decreased from 37.2±8.0 (before tr-
eatment) to 34.8±5.5 mm/m
2 (after treatment) (p=0.136) and LVESd 
decreased from 27.6±5.9 to 25.7±4.0 mm/m
2 (p=0.05) (Fig. 2A). In 
Table 2. Echocardiographic parameters before and after treatment with 
enalapril (n=13)
Before Tx. After Tx. p
BSA (m
2) 1.27±0.32 1.33±0.29 0.110 
LVEDd (mm/m
2) 37.2±8.0 34.8±5.5 0.136 
LVESd (mm/m
2) 27.6±5.9 25.7±4.0 0.050 
LVEDv (mL/m
2) 48.6±15.7 49.1±13.2 0.110 
LVESv (mL/m
2) 23.8±8.7 25.5±11.4 0.051 
FS (%) 25.8±2.1 26.6±3.0 0.241 
EF (%) 51.0±4.8 50.4±9.3 0.878 
LV Tei 0.31±0.13 0.38±0.24 0.126 
LV GS (%) -18.1±3.1 -16.8±4.5 0.286 
E velocity (m/sec) 0.92±0.16 0.87±0.14 0.108 
A velocity (m/sec) 0.49±0.1 0.47±0.1 0.582 
E/A ratio 1.93±0.48 1.94±0.64 0.638 
Septal Sm (cm/sec) 6.8±1.1 6.3±0.9 0.196 
Septal Em (cm/sec) 10.9±1.7 11.2±2.4 0.952 
Septal Am (cm/sec) 4.8±1.2 4.8±1.0 0.366 
Septal Em/Am ratio 2.5±0.8 2.4±0.7 0.328 
LVFW Sm (cm/sec) 9.1±2.8 7.0±2.2 0.032 
LVFW Em (cm/sec) 14.4±3.8 12.1±4.0 0.089 
LVFW Am (cm/sec) 5.6±1.9 4.5±1.2 0.121 
LVFW Em/Am ratio 2.8±1.1 2.8±1.0 0.666 
LV mass index (g/m
2) 68.3±12.9 66.8±14.6 0.646 
Data are presented as the mean±SD. BSA: body surface area, LVEDd: in-
dexed LV end-diastolic diameter, LVESd: indexed LV end-systolic diameter, 
LVEDv: indexed LV end-diastolic volume, LVESv: indexed LV end-systolic 
volume, FS: fractional shortening, EF: ejection fraction, GS: peak global lon-
gitudinal strain at 4 chamber view, LVFW: LV free wall, LV: left ventricular, 
Sm: systolic myocardial velocity, Em: early diastolic myocardial velocity187 Hye Won Kwon, et al.
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the carvedilol group, LVEDd decreased from 32.0±6.1 to 31.2±5.6 
mm/m
2 (p=0.285) and LVESd decreased from 23.5±4.7 to 22.3±4.6 
mm/m
2 (p=0.241) (Fig. 2B). 
In all 23 subjects, LVEDd decreased from 34.9±7.6 to 33.2±5.7 
mm/m
2 (p=0.077) and LVESd significantly decreased from 25.8±5.7 
to 24.1±4.5 mm/m
2 (p=0.023) (Fig. 3A and B). In all patients, LVEDv 
and LVESv did not change significantly. LV mass index also de-
creased from 67.9±18.5 to 63.8±17.6 g/m
2 without statistical sig-
nificance (p=0.421). 
 
Left ventricular systolic and diastolic function
In the enalapril group, LV FS increased from 25.8±2.1 to 26.6± 
3.0% (p=0.241) and LV EF decreased from 51.0±4.8 to 50.4±9.3% 
(p=0.878) (Fig. 2A). In the carvedilol group, LV FS increased from 
26.4±1.1 to 28.6±4.2% (p=0.110) and LV EF improved from 48.4± 
4.0 to 53.8±6.8% (p=0.074) (Fig. 2B), but this effect was not statis-
tically significant. LV Tei index improved significantly after treatment 
from 0.41±0.08 to 0.28±0.06 (p=0.009) in the carvedilol group.
In all 23 subjects, LV FS significantly increased from 26.1±1.7 to 
27.6±3.7 (p=0.046), and LV EF increased from 49.8±4.6 to 52.1± 
8.2% (p=0.156) without statistical significance (Fig. 3C and D). In 
all the patients, systolic myocardial velocities at the basal seg-
ments of the LV free wall (LVFW Sm) changed significantly from 
9.1±2.4 to 7.5±2.0 (p<0.005), but the LV septal wall (Septal Sm) did 
not change significantly (p=1.0). LV peak global longitudinal strain 
and E/A ratio showed no significant change before and after treat-
ment in all the subjects. These findings were compatible with the re-
sult of overall diastolic myocardial velocities at the basal segments 
of the LV free wall (LVFW Em/Am) and septal wall (septal Em/Am). 
Brain natriuretic peptide level
In the enalapril group, the average BNP level increased from 14.7± 
6.4 to 292.2±887.1 pg/mL (p=0.753). One patient from this group 
died from uncompensated heart failure at the age of 14 years (20 
months after first enalapril prescription); his BNP level increased 
from 16 to 2817 pg/mL. In the carvedilol group, the average BNP le-
Table 4. Echocardiographic parameters before and after treatment (n=23)
Before Tx. After Tx. p
BSA (m
2) 1.34±0.33 1.42±0.31 <0.001
LVEDd (mm/m
2) 34.9±7.6 33.2±5.7 0.077 
LVESd (mm/m
2) 25.8±5.7 24.1±4.5 0.023 
LVEDv (mL/m
2) 49.7±14.3 47.7±12.9 0.831 
LVESv (mL/m
2) 25.0±8.2 26.0±11.6 0.653 
FS (%) 26.1±1.7 27.6±3.7 0.046 
EF (%) 49.8±4.6 52.1±8.2 0.156 
LV Tei 0.35±0.12 0.33±0.18 0.277 
LV GS (%) -17.7±3.0 -17.4±3.6 0.466 
E velocity (m/sec) 0.87±0.15 0.89±0.12 0.910 
A velocity (m/sec) 0.49±0.12 0.47±0.09 0.314 
E/A ratio 1.86±0.54 1.95±0.52 0.465 
Septal Sm (cm/sec) 6.7±1.0 6.8±1.2 1.000 
Septal Em  (cm/sec) 11.1±1.5 11.3±2.1 0.724 
Septal Am  (cm/sec) 4.9±1.2 5.2±1.1 0.058 
Septal Em/Am ratio 2.4±0.8 2.2±0.6 0.122 
LVFW Sm (cm/sec) 9.1±2.4 7.5±2.0 0.005 
LVFW Em (cm/sec) 14.3±3.5 13.6±3.7 0.530 
LVFW Am (cm/sec) 5.6±1.8 5.1±1.4 0.382 
LVFW Em/Am ratio 2.9±1.1 2.8±0.8 0.638 
LV mass index (g/m
2) 67.9±18.5 63.8±17.6 0.421 
Data are presented as the mean±SD. BSA: body surface area, LVEDd: LV 
end-diastolic diameter, LVESd: LV end-systolic diameter, LVEDv: LV end-dia-
stolic volume, LVESv: LV end-systolic volume, FS: fractional shortening, EF: 
ejection fraction, GS: peak global longitudinal strain at 4 chamber view, 
LVFW: LV free wall, LV: left ventricular, Sm: systolic myocardial velocity, Em: 
early diastolic myocardial velocity
Table 3. Echocardiographic parameters before and after treatment with 
carvedilol (n=10)
Before Tx. After Tx. p
BSA (m
2) 1.44±0.33 1.54±0.3 0.005 
LVEDd (mm/m
2) 32.0±6.1 31.2±5.6 0.285 
LVESd (mm/m
2) 23.5±4.7 22.3±4.6 0.241 
LVEDv (mL/m
2) 51.2±13.2 46.0±13.1 0.208 
LVESv (mL/m
2) 26.5±7.6 26.6±12.6 0.674 
FS (%) 26.4±1.1 28.6±4.2 0.110 
EF (%) 48.4±4.0 53.8±6.8 0.074 
LV Tei 0.41±0.08 0.28±0.06 0.009 
LV GS (%) -17.3±2.9 -18.2±2.3 0.260 
E velocity (m/sec) 0.81±0.12 0.91±0.1 0.114 
A velocity (m/sec) 0.50±0.14 0.48±0.1 0.333 
E/A ratio 1.78±0.64 1.97±0.37 0.114 
Septal Sm (cm/sec) 6.7±0.9 7.3±1.4 0.084 
Septal Em (cm/sec) 11.3±1.1 11.5±1.8 0.717 
Septal Am (cm/sec) 5.1±1.1 5.7±0.9 0.084 
Septal Em/Am ratio 2.4±0.8 2.0±0.3 0.169 
LVFW Sm (cm/sec) 9.1±2.0 8.1±1.7 0.089 
LVFW Em (cm/sec) 14.2±3.2 15.4±2.4 0.238 
LVFW Am (cm/sec) 5.5±1.8 5.8±1.4 0.774 
LVFW Em/Am ratio 2.9±1.2 2.7±0.5 0.799 
LV mass index (g/m
2) 67.3±24.9 60.5±20.8 0.260 
Data are presented as the mean±SD. BSA: body surface area, LVEDd: LV 
end-diastolic diameter, LVESd: LV end-systolic diameter, LVEDv: LV end-dia-
stolic volume, LVESv: LV end-systolic volume, FS: fractional shortening, EF: 
ejection fraction, GS: peak global longitudinal strain at 4 chamber view, 
LVFW: LV free wall, LV: left ventricular, Sm: systolic myocardial velocity, Em: 
early diastolic myocardial velocity188  Enalapril and Carvedilol Against Cardiomyopathy in Muscular Dystrophy
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vel increased from 15.8±8.6 to 21.0±15.8 pg/mL (p=0.374).
Drug adverse effect
In the enalapril group, mild intermittent cough was observed in 2 
patients. Another patient reported mild transient dizziness. Those 
side effects subsided with time; therefore, patients continued the me-
dication. No patient developed adverse effects with the use of car-
vedilol during the study period. The absence of hypotension, brady-
cardia, or any other significant symptom in patients undergoing 
carvedilol treatment was probably related to the gradual up-titration 
dose protocol and due to the fact that most patients were non-
ambulatory.
Discussion
This study demonstrated that enalapril or carvedilol therapy can be 
initiated safely in middle childhood (school age) and adolescent pa-
tients with DMD or BMD. Most patients appeared to tolerate enala-
pril or carvedilol therapy well without significant adverse effects. Af-
ter treatment, LV FS improved significantly in all 23 patients, even 
though the increase was not significantly improved in the individ-
ual groups. This result might be due to the small sample size of each 
group. 
The mechanism underlying the effect of ACE inhibitors, such as 
enalapril, in adult heart failure is well documented. Both angioten-
sin II and aldosterone contribute to the formation of fibrosis and ov-
ergrowth of the connective tissue in the heart. Angiotensin II acts 
as a growth factor at sites of tissue repair and enhances the activity 
of fibrogenic cytokines.
17) Likewise, aldosterone is involved in the 
synthesis of fibrosis-forming collagen and reduces compliance of 
the heart.
18) These harmful consequences of renin-angiotensin-al-
dosterone system hyperactivity further complicate myocardial fi-
brosis resulting from dystrophin deficiency in DMD and BMD pati-
ents.
5) Therefore, the use of ACE inhibitors, angiotensin receptor blo-
ckers, or aldosterone antagonists in DMD and BMD patients with 
cardiomyopathy is indicated. ACE inhibitors have been studied more 
and, as a result, are prescribed more frequently.
7-9)19) The efficacy of 
angiotensin receptor blockers has not been studied in large trials 
with DMD or BMD patients presenting DCM.
5)
Patients with DCM often have elevated levels of circulating cat-
echolamines, presumably reflecting overactivity of the sympathetic 
nervous system.
20) This condition is thought to exacerbate their LV 
dysfunction and forms the basis for the rationale supporting the use 
of β-blocker therapy for patients with DCM. Carvedilol, a mild β1-
Fig. 2. Left ventricular (LV) changes in dimension and systolic function before and after treatment in the enalapril-treated (A) and carvedilol-treated (B) groups. 
Patients of both groups showed decreased LV end-diastolic and end-systolic dimension, but the effect was not statistically significant. LV fractional shortening 
(FS) showed slight improvement in both groups after treatment, but without statistical significance. LVEDd: LV end-diastolic diameter, LVESd: LV end-sys-
tolic diameter, EF: ejection fraction.
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selective adrenergic blocking agent with vasodilating effects due 
to α-blocking, antioxidant, and anti-proliferative properties, produc-
es clinical benefits in patients with moderate to severe heart failure 
without serious side effects.
21)22) Overactivity of the sympathetic 
nervous system also plays a role in the pathophysiology of the DCM 
associated with DMD and BMD.
4) Hence, carvedilol therapy could 
provide benefits for DMD and BMD patients with DCM. 
It is also possible that the combined use of an ACE inhibitor with 
a β-blocker can remarkably improve the survival rate of DMD pa-
tients with heart failure, as has been shown for other patients with 
heart failure.
6)23-25) We could prescribe another drug (an ACE inhibi-
tor or a β-blocker) to a patient if the cardiac function deteriorates 
at the follow-up echocardiography even after treatment.
The American Academy of Pediatrics has recommended that car-
diac care of a patient with DMD or BMD should begin after confirm-
ation of the diagnosis and a complete cardiac evaluation (including 
a history and physical examination, electrocardiography, and echo-
cardiography) should be started at approximately 10 years of age.
26) 
Our policy regarding cardiac evaluation is that all patients with DMD 
or BMD undergo echocardiography at diagnosis, every 2 years up 
to the age of 10, and annually thereafter. Early detection of LV dys-
function and early use of drugs such as ACE inhibitors and β-bloc-
kers - especially carvedilol - would be beneficial for delaying pro-
gression or improvement of heart failure in DMD patients. 
Previous studies demonstrated that tissue Doppler imaging can 
identify myopathic changes earlier and reflect ongoing damage to 
the myocardium. Therefore, the technique may be helpful in assess-
ing LV dysfunction at an early stage of the disease.
27-29) In our study, 
tissue Doppler echocardiography did not show consistently signifi-
cant changes from before treatment to after treatment. Because 
we did not determine these parameters in healthy adolescents, we 
could not evaluate the importance of tissue Doppler imaging in 
the early detection of LV dysfunction. 
Elevated plasma BNP levels in patients with LV dysfunction can 
predict prognosis.
30) However, the increase in plasma BNP levels in 
muscular dystrophy patients with LV systolic dysfunction is often 
minimal. Indeed, Mori et al.
31) demonstrated that the increase in 
plasma BNP levels is minimal when the LV FS is >15%, but remark-
able when LV FS is <15%. The authors explained that this might be 
due to 2 reasons. First, BNP increases in response to exercise in pa-
tients with DCM. Most patients older than 10 years with DMD 
were wheelchair-dependent and the effect of exercise on natriuretic 
peptide levels is negligible until their cardiac function is severely 
diminished.
31) Second, cardiac myocytes become replaced by fibrous 
tissue in patients with DMD. Therefore, the synthesis of natriuretic 
peptides by the heart may be reduced.
31) In patients with decreased 
systolic function, repeated measurement of plasma natriuretic pep-
tides is important because an increase in the plasma BNP levels may 
Fig. 3. Left ventricular (LV) changes in dimension and systolic function before and after treatment with enalapril or carvedilol. Overall end-diastolic dimension 
(LVEDd) and end-systolic LV dimension (LVESd) decreased after treatment with enalapril or carvedilol for 20.1±8.9 months (A and B). Overall LV fractional short-
ening (FS) increased significantly (C). Ejection fraction (EF) showed slight improvement after treatment, but without statistical significance (C and D).
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suggest severe LV dysfunction in patients with muscular dystrophy. 
In conclusion, administration of enalapril or carvedilol could im-
prove LV systolic function and prevent the progression of LV dila-
tation to some degree in middle childhood and adolescent patients 
with muscular dystrophy without significant adverse effects.
Study limitations
The number of patients in each group was too small to obtain st-
atistically significant data. Therefore, randomized, controlled, pro-
spective long-term trials with a large patient population are required 
to determine the effect of enalapril or carvedilol on overall survival 
and to more clearly define their role in treatment of patients with mu-
scular dystrophy.
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